AZ Divests Arimidex And Casodex Rights To Juvisé
Banks Upfront Payment Of $181m
Selling off the two cancer drugs to the French firm is the latest example of AstraZeneca's strategy of reducing its portfolio of mature assets to boost its R&D budget.
You may also be interested in...
Allergan is selling its Crohn’s disease and ulcerative colitis drug brazikumab back to AstraZeneca to satisfy regulators ahead of its link-up with AbbVie, essentially giving the asset to the UK major for free.
Deal with Pfizer makes for Theravance’s third large pharma partnership since 2016. AbbVie off-loads Marinol to India’s Alkem, Bausch licenses candidate for rare form of dry eye disease from Novaliq.
News that the UK government will not procur any doses of AstraZeneca’s Evusheld for the prevention of COVID-19 infections in immunocompromised people has been greeted with dismay and the move will hurt the combo's already-limited sales growth.